Doximity’s (NASDAQ:DOCS) defence rests on trusted clinician identity, ease of use, and workflow familiarity. The challenge is ...

Doximity sees artificial intelligence as a major tailwind for the company just six months after acquiring Pathway Medical to ...

Doximity's stock is sinking on conservative guidance, but its long-term investment thesis remains intact.

Doximity Inc DOCS reported third-quarter results for fiscal 2026 after the market close on Thursday, and shares are tumbling. Here’s what you need to know. Doximity stock is testing lower boundaries.

Doximity's new AI oversight initiative has seen "tremendous enthusiasm" ahead of its release, Topol told Newsweek.

Fintel reports that on February 9, 2026, Canaccord Genuity upgraded their outlook for Doximity (NYSE:DOCS) from Hold to Buy.

Doximity (DOCS) has drawn fresh attention after a sharp pullback, with the stock showing declines over the past week, month and past 3 months, while the business continues to report revenue and net ...

Detailed price information for Doximity Inc Cl A (DOCS-N) from The Globe and Mail including charting and trades.

Doximity (NYSE:DOCS) reported “solid” fiscal third-quarter 2026 results, highlighting revenue and profitability that exceeded ...

William Blair sold 372,184 shares of Doximity; estimated trade size was $20.89 million (quarterly average pricing). Quarter-end Doximity position value fell by $184.77 million, reflecting both trading ...

Futures are trading lower after an incredible turnaround on Friday, with all major indices surging higher following a three-day massive sell-off that had pushed the stock market to the brink of a ...

Q3 2026 earnings call recap: revenue, margins, guidance, AI adoption, MFN headwinds and buybacks—get key takeaways and act now.